{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T01:15:59Z","timestamp":1770513359062,"version":"3.49.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003969","name":"Iran Ministry of Health and Medical Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003969","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.vhri.2022.10.001","type":"journal-article","created":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T11:57:56Z","timestamp":1672660676000},"page":"78-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Cost-Effectiveness Analysis of Macitentan in Comparison With Bosentan in the Treatment of Pulmonary Arterial Hypertension in Iran"],"prefix":"10.1016","volume":"34","author":[{"given":"Mahna","family":"Ekhlasi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiva","family":"Sheikhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra Karimi","family":"Majd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farzad","family":"Peiravian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nazila","family":"Yousefi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.vhri.2022.10.001_bib1","first-page":"363","article-title":"World Health Organization group I pulmonary hypertension: epidemiology and pathophysiology","volume":"34","author":"Prins","year":"2016","journal-title":"Cardiol Clin"},{"issue":"16","key":"10.1016\/j.vhri.2022.10.001_bib2","first-page":"2250","article-title":"A\u00a0report of the American College of Cardiology Foundation task force on expert consensus documents and the American Heart Association","volume":"119","author":"McLaughlin","year":"2009","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.vhri.2022.10.001_bib3","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/rccm.200510-1668OC","article-title":"Pulmonary arterial hypertension in France: results from a national registry","volume":"173","author":"Humbert","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.vhri.2022.10.001_bib4","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1183\/09031936.00092306","article-title":"An epidemiological study of pulmonary arterial hypertension","volume":"30","author":"Peacock","year":"2007","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.vhri.2022.10.001_bib5","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1378\/chest.10-0075","article-title":"The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US contemporary registries","volume":"139","author":"Frost","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.vhri.2022.10.001_bib6","unstructured":"Tran K, Coyle K, Jabr MF, et\u00a0al. Canadian Agency for Drugs and Technologies in Health Agence Canadienne Des M\u00e9dicaments et des Technologies de la Sant\u00e9 CADTH Therapeutic Review Report Drugs for Pulmonary Arterial Hypertension: Comparative Efficacy, Safety, and Cost-Effectiveness; (March); 2015."},{"issue":"2","key":"10.1016\/j.vhri.2022.10.001_bib7","first-page":"72","article-title":"Pulmonary hypertension registry: a 10-year experience (Persian)","volume":"37","author":"Malekmohammad","year":"2019","journal-title":"J\u00a0Counc Islam Repub Iran"},{"issue":"3","key":"10.1016\/j.vhri.2022.10.001_bib8","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.chest.2018.11.030","article-title":"Therapy for pulmonary arterial hypertension in adults: update of the CHEST guideline and expert panel report","volume":"155","author":"Klinger","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.vhri.2022.10.001_bib9","author":"Rich"},{"key":"10.1016\/j.vhri.2022.10.001_bib10","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/j.vhri.2019.08.409","article-title":"PRO1 medical therapy for pulmonary arterial hypertension (PAH): an indirect treatment comparison of macitentan and bosentan","volume":"19","author":"Di Scala","year":"2019","journal-title":"Value Health Reg Issues"},{"issue":"1","key":"10.1016\/j.vhri.2022.10.001_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchf.2014.07.013","article-title":"Effect of macitentan on hospitalizations: results from the SERAPHIN trial","volume":"3","author":"Channick","year":"2015","journal-title":"JACC Heart Fail"},{"issue":"1","key":"10.1016\/j.vhri.2022.10.001_bib12","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1080\/10717544.2018.1523257","article-title":"A\u00a0Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension","volume":"25","author":"Wang","year":"2018","journal-title":"Drug Deliv"},{"issue":"3","key":"10.1016\/j.vhri.2022.10.001_bib13","doi-asserted-by":"crossref","first-page":"239","DOI":"10.21037\/cdt.2019.03.02","article-title":"A\u00a0network meta-analysis for safety of endothelin receptor antagonists in pulmonary arterial hypertension","volume":"9","author":"Zhang","year":"2019","journal-title":"Cardiovasc Diagn Ther"},{"issue":"5","key":"10.1016\/j.vhri.2022.10.001_bib14","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s40256-019-00392-y","article-title":"Evolution of patients with pulmonary arterial hypertension starting macitentan after the discontinuation of other endothelin-receptor antagonists: results of a retrospective study","volume":"20","author":"Cadenas-Men\u00e9ndez","year":"2020","journal-title":"Am J Cardiovasc Drugs"},{"issue":"6","key":"10.1016\/j.vhri.2022.10.001_bib15","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1080\/03007995.2020.1756234","article-title":"Long-term treatment of pulmonary arterial hypertension with macitentan in Japanese patients","volume":"36","author":"Tahara","year":"2020","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"10.1016\/j.vhri.2022.10.001_bib16","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1177\/1060028019888760","article-title":"A\u00a0Bayesian network meta-analysis of add-on drug therapies specific for pulmonary arterial hypertension","volume":"54","author":"Petrovi\u010d","year":"2020","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1016\/j.vhri.2022.10.001_bib17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"Gali\u00e8","year":"2016","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.vhri.2022.10.001_bib18","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.4103\/jfmpc.jfmpc_1166_19","article-title":"Cost-utility analysis of macitentan vs. bosentan in pulmonary atrial hypertension","volume":"9","author":"Nosrati","year":"2020","journal-title":"J\u00a0Fam Med Prim Care"},{"key":"10.1016\/j.vhri.2022.10.001_bib19","unstructured":"Official Healthcare Services Price List in Public and Private Sectors in Iran. Published Online\u00a02020."},{"issue":"9","key":"10.1016\/j.vhri.2022.10.001_bib21","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.vhri.2022.10.001_bib22","first-page":"363","article-title":"WHO group I pulmonary hypertension: epidemiology and pathophysiology","volume":"34","author":"Thenappan","year":"2017","journal-title":"Cardiol Clin"},{"issue":"5","key":"10.1016\/j.vhri.2022.10.001_bib24","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40273-015-0366-8","article-title":"Cost effectiveness of first-line oral therapies for pulmonary arterial hypertension: a modelling study","volume":"34","author":"Coyle","year":"2016","journal-title":"Pharmacoeconomics"},{"issue":"34","key":"10.1016\/j.vhri.2022.10.001_bib25","first-page":"135","article-title":"Estimation of social discount rate for Iran","volume":"9","author":"Abdoli","year":"2009","journal-title":"Econ Res Rev"},{"issue":"1","key":"10.1016\/j.vhri.2022.10.001_bib28","doi-asserted-by":"crossref","DOI":"10.1177\/2045894018816294","article-title":"Treatment patterns, healthcare resource utilization, and healthcare costs among patients with pulmonary arterial hypertension in a real-world US database","volume":"9","author":"Studer","year":"2018","journal-title":"Pulm Circ"},{"issue":"3","key":"10.1016\/j.vhri.2022.10.001_bib29","first-page":"72","article-title":"[Pharmacoeconomic aspects of macitentan in the therapy of pulmonary arterial hypertension]","volume":"89","author":"Moiseeva","year":"2017","journal-title":"Ter Arkh"},{"issue":"8","key":"10.1016\/j.vhri.2022.10.001_bib30","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1111\/j.1524-4733.2009.00568.x","article-title":"The cost-effectiveness of bosentan in the United Kingdom for patients with pulmonary arterial hypertension of WHO functional class III","volume":"12","author":"Stevenson","year":"2009","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.vhri.2022.10.001_bib31","first-page":"393","article-title":"Treatment patterns and resource utilization and costs among patients with pulmonary arterial hypertension in the United States","volume":"13","author":"Angalakuditi","year":"2010","journal-title":"J\u00a0Med Econ"},{"issue":"4","key":"10.1016\/j.vhri.2022.10.001_bib32","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1586\/14737167.2016.1120672","article-title":"Cost-utility and budget impact analysis of drug treatments in pulmonary arterial hypertension associated with congenital heart diseases in Thailand","volume":"16","author":"Thongsri","year":"2016","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"10","key":"10.1016\/j.vhri.2022.10.001_bib33","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2165\/11317820-000000000-00000","article-title":"Cost-utility of treatments for pulmonary arterial hypertension","volume":"29","author":"Garin","year":"2009","journal-title":"Clin Drug Investig"},{"issue":"7","key":"10.1016\/j.vhri.2022.10.001_bib34","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1002\/ppul.25427","article-title":"Systematic review and cost-effectiveness of bosentan and sildenafil as therapeutic drugs for pediatric pulmonary arterial hypertension","volume":"56","author":"Chen","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.vhri.2022.10.001_bib35","first-page":"239","article-title":"Cost minimization analysis of endothelin receptor antagonists for the treatment of pulmonary arterial hypertension in the Netherlands","volume":"150","author":"Tariq","year":"2015","journal-title":"Wetenschappelijk Platform EMF Nederland"},{"issue":"1","key":"10.1016\/j.vhri.2022.10.001_bib36","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF03256167","article-title":"Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis","volume":"8","author":"Dranitsaris","year":"2010","journal-title":"Appl Health Econ Health Policy"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109922001881?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109922001881?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:14:31Z","timestamp":1761941671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109922001881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":32,"alternative-id":["S2212109922001881"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2022.10.001","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness Analysis of Macitentan in Comparison With Bosentan in the Treatment of Pulmonary Arterial Hypertension in Iran","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2022.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}